Study Enrollment

Your details will not be published or shared.

Clinical Trial

Role of blood flow on artery function and exercise capacity in cystic fibrosis (CF-FLOW)

Cystic fibrosis has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknown. Our laboratory recently published the first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is reasonable to suspect that the blood vessels are involved with exercise intolerance in CF. This study will look at how 1) blood flow and 2) artery function contribute to exercise capacity in CF.

Eligibility Criteria

  • Inclusion Criteria Clinical diagnosis of cystic fibrosis Use traditional CF treatment medications Have been clinically stable for at least two weeks Exclusion For Participants <18 years <30% to >85% of predicted For Participants ?18 years, FEV1 <30% to >80% of predicted Frank pulmonary hypertension diagnosed by Cardiac ECHO with Right Ventricular Systolic Pressure (RVSP) >45 mm hg

Contact Information

    Ryan Harris

    (706) 721-5998